Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study. J of Skin [Internet]. 2019 Nov. 9 [cited 2025 Apr. 7];3:S34. Available from: https://skin.dermsquared.com/skin/article/view/761